Bristol Myers Squibb And The New Wave Of Cancer Drugs | Latest News RSS feed

Bristol Myers Squibb And The New Wave Of Cancer Drugs - Latest News


Bristol Myers Squibb And The New Wave Of Cancer Drugs

Even with the best cancer drugs, doctors are forced to switch from one therapy to the next as the tumors rapidly develop resistance. A new wave of immunotherapy drugs, in the spotlight of the upcoming ... read more

Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy

The cash deal comes on the heels of Bristol-Myers Squibb ... hopes of a new wave of large healthcare acquisitions. Loxo gained prominence in 2017 - just three years after going public - with impressiv... read more

Bristol-Myers to buy cancer drug company Celgene for $74B

3 (UPI) --Bristol-Myers Squibb announced Thursday it will buy the cancer drug company Celgene for $74 ... nearly 5 percent of people over 11 abuse opioids New immunology and inflammation drugs that ar... read more

Looking for another news?


Bristol Myers suffers again after more Keytruda success

Shares in Bristol Myers Squibb (NYSE: BMY) tumbled again as rival Merck's (NYSE:MRK) immunotherapy drug Keytruda.scored well ... Keytruda is part of the new wave of immunotherapy boosting treatments f... read more


Bristol's drug pricing under fire as UK agency rejects Opdivo

LONDON (Reuters) - Bristol-Myers Squibb’s closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treat... read more

Bristol-Myers Squibb’s $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert

The $74 billion cash-and-stock buyout has the potential to accelerate the development of new treatments ... portfolio of Bristol-Myers Squibb and Celgene includes nine drugs, each with over $1 billion ... read more

Here’s What Bristol-Myers Squibb Will Look Like After Acquiring Celgene

Once Bristol-Myers Squibb completes ... the leukemia drug Sprycel, and the melanoma drug Yervoy. And following this deal, it will also market the multiple-myeloma drugs Revlimid and Pomalyst, plus the ... read more

Top Cancer Doctor, Forced Out Over Ties to Drug Makers, Joins Their Ranks

Dr. Baselga stepped down in September from his role as chief medical officer at the cancer center after The New York Times and ProPublica ... He later resigned from the boards of the drug maker Bristo... read more

Advances in Cancer Drugs Fuel Blockbuster Deal

Bristol-Myers Squibb Co.’s blockbuster $ ... particularly in the $123 billion world-wide market for cancer drugs, now one of the biggest pharmaceutical sectors. Major scientific advances have led to g... read more

Bristol cancer, clot drugs drive profit beat, shares rise

Oct 27 (Reuters) - Bristol-Myers Squibb ... drug, hepatitis C treatments and its Eliquis blood clot preventer. Company shares rose 1.9 percent in premarket trading. Bristol-Myers is considered the lea... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us